Personalized Medicine Conference Recap

February 6, 2010

Genetics and pharmacogenomics took center stage at the Personalized Medicine World Conference in Mountain View, CA.

A larger part of the discussion was centered around how we will collect, handle, standardize, store and process all the information on each of us for healthcare.

Attendees were an interesting mix of angel investors, academics, representatives from governmental agencies, institutional investors, pharma, information technologists, bioethicists, hospitals, patients and consultants. Currently, the field of personalized medicine is a mix of all these players, looking for the next healthcare technology play.

Large IT companies that wouldn’t normally be thought of as healthcare attended, IBM and Dell both gave talks. A major focus for the IT companies were EHR‘s or Electronic Health Records. As the types of data multiplies, a way to handle digitized X-rays, test results, prescriptions and clinician notes will need to be found and integrated. For a savvy technologist who can understand what kinds of information clinicians/doctors need at a glance, there is a definite business opportunity.

One point of note, Dr. Amos from NIST stated governmental agencies have a vested interest in making sure biological test results have standards- so your results from one lab will be able to be interpreted by any doctor down the line. Coming up with these standards will likely be a long process involving both government, healthcare workers and industry.

Contributed by Chia Hwu, follow me on Twitter @chiah.


Mello Biotech’s Tech Can Create Stem Cells

February 6, 2010

Mello Biotech, providers of a potential method for creating stem cells, had a booth on the expo floor at the Cambridge Healthtech Institute‘s 17th International Molecular Medicine Tri-Conference.

The basic idea is to introduce microRNA into a mature cell and reprogramming it to a stem cell state, capable of becoming any other kind of cell. The claim is that this process can create stem cells with as few as 400 mature cells (approximately the number in a hair follicle). The technology Mello Biotech uses is electroporation to deliver the microRNA into a cell, removing the need for a viral vector to deliver RNA.

There has been work done with creating stem cells with retroviruses mediating the RNA transfer; the concern is that viral gene insertion could  be random and disrupt normal functioning of the cells.

So far, the company claims that they have created all three types of cells from the different layers of skin from a stem cell created through their process. The challenge will be to create other types of cells (kidney, liver, heart, nerve etc.) from stem cells created through this process.

If this technology is as efficient as the company claims and these cells can be used in treatment, stem cell therapy will be a reality.

Contributed by Chia Hwu, follow me on Twitter @chiah.


Top Ten Venture Deals Highlight Interest In Online Services, Healthcare

July 21, 2009

Second-quarter venture investing showed a modest 15 percent rebound from the depths of the dismal first quarter. But it was no great shakes.

Workday raised $75 million, the most of any IT company in the second quarter

Workday raised $75 million, the most of any IT company in the second quarter

Investments were still down 51 percent from a year ago, and there were no obvious signs of a coming uptick in spending.

In this environment, the top ten deals of the quarter reflected a restrained level of optimism about healthcare investing (now that the Obama Administration has raised hopes of healthcare reform) and online service delivery. These are themes are likely to continue in the months ahead, even if the negative cast of the industry remains.

The top deal of the quarter, according to the National Venture Capital Association, PricewaterhouseCoopers and Thomson Reuters, went to biotech firm Clovis Oncology of Boulder, CO, which raised $140 million. The company is working on anti-cancer drugs.

Three other healthcare transactions made the list: Hyperion Therapeutics of South San Francisco; PhotoThera of Carlsbad; and Cempra Pharmaceuticals of Chapel Hill, NC. Hyperion took in $60 million, PhotoThera, $50 million and Cempra, $46 million.

Companies developing software or online services were led by Workday of Pleasanton, which raised $75 million from Greylock Partners and New Enterprise Associates. The company develops software delivered as a service to human resources departments.

ExactTarget of Indianapolis raised almost $70 million and Revolution Money of St Petersburg, FL, took in $42 million. Security services company LifeLock of Tempe, AZ, raised about $40 million.

Also on the top ten list as well were Phoenix Services of Unionville, PA, and Fusion-io of Salt Lake City.

It is not surprising to see VCs pour buckets of money into later stage and expansion deals since the nation’s public markets refuse. (Most of the IT deals on the list fell into this category.) The question is whether there will be big paydays for some of these more mature companies.

My bet is there could be, but not until more sustained optimism returns to Wall Street.


Healthcare Is A Venture Capital Bright Spot And Psilos Group Explains Why

July 20, 2009

The economy is down, the IPO market stalled and venture capitalists are sitting on their wallets instead of opening them.

So why is an admittedly apprehensive investor like Albert Waxman spending money at roughly the same pace as last year?

I think you will see entrepreneurs respond to the healthcare crisis, says Psilos Albert Waxman.

"I think you will see entrepreneurs respond to the healthcare crisis," says Psilos' Albert Waxman.

“We’re very cautious,” acknowledges the CEO and senior managing member of Psilos Group. But startup pricing is down and fewer firms are willing to compete for deals, he says.

The net result is Psilos expects two and three deals this year, including an investment in Gamma Medica-Ideas that Waxman hopes to close within 45 days. Gamma Medica develops more effective and lower cost technology for breast screenings.

Waxman is clearly not alone in applying a steady approach to venture capital. Healthcare proved a relative bright spot in an otherwise dim VC investment horizon in the second quarter.

Spending on startups rose 62 percent from the first quarter and for the first time outpaced investments in information-technology companies. The sector sprung back to spending levels before the financial collapse last fall.

Waxman says his aim is to find companies using information technology in the health-care market. There are enormous opportunities for these firms, especially with the health-care push coming from the Obama Administration.

“I think we will see entrepreneurs respond to the healthcare crisis and the business opportunities it creates,” says Waxman.

For many VCs, healthcare is becoming the new frontier. The industry has a desperate need of technology to improve efficiencies and lower costs. Thirty years into the technology revolution, its use of technology is still crude, says Waxman, and this at a time when the world needs big changes in patient care.

Whether there is money to be made is another question. But for now, change is on the horizon and that spells opportunity for those willing to take a chance.


Judy Estrin: Risk Adversed Investors, Short Term Greed, Fear Of Failure, Are Stifling Innovation

May 14, 2009
To spur innovation, book author and entrepreneur Judy Estrin suggests an overhaul of the U.S. education system, more research and academia investing and the return of risk taking

To spur innovation, book author and entrepreneur Judy Estrin suggests an overhaul of the U.S. education system, more research and academia investing and the return of risk taking

Is innovation really slowing down in Silicon Valley?

I caught up this morning with serial entrepreneur Judy Estrin (former Cisco CTO) who was giving a talk at the Computer History Museum on innovation (or the lack thereof); most of it based on her book Closing the Innovation Gap.

Estrin argued that what is stiffling innovation are risk adversed venture capitalists and overall short term greed, especially since the Internet bubble in the late 90s.

“I’m not saying that there is no innovation going on. But that the innovation support structure in the country has become much more short term focus and not as deep and broad as before. Meaning that the opportunities that I had to build my career don’t exist anymore,” said Estrin.

Silicon Valley is still the world’s innovation hotbed

Although Silicon Valley is a much richer environment than anywhere else in the country or certainly any place in the world, that’s not good enough, points Estrin who sees 2 main culprits for the decline in innovation:

  1. the risk adverse investors in Silicon Valley. Failure is a critical part of innovation. You have to be able to try things even if you don’t know the outcome. You also inspire innovation when you turn threats into challenges and not fear;
  2. and the short term view of both investors and entrepreneurs who want to strike it big and quick. One of Estrin’s core values is patience and tenacity. You need to give time to an idea to develop

“It went from the passion of building a company and changing the world to how much can we make in 2-years. The dynamics have shifted,” adds Estrin who recalled a venture capitalist telling her to come back with several customers before he invests in her start-up.

Here are Estrin’s 5 core values behind innovation: questioning (both yourself and others without being judgmental and the tone matters), risk, openness (sharing, collaboration), patience (tenacity) and trust.

Cleantech and Healthcare are the 2 huge opportunities of this downturn

Estrin also argues that dramatic innovation is needed to help repay the massive deficit and to create the millions of jobs lost.

“Normal growth will not solve those 2 key problems because the companies that laid-off will not rehire the employees. So the only way to solve it is through dramatic innovation that will create new industries,” adds Estrin.

For the 7th-time entrepreneur, energy and environment (cleantech) and healthcare (medicine, wellness, care of elderness…) could be the answer. “A crisis is a terrible thing to waste,” jokes Estrin.

More government investments, corporate incentives will foster innovation

The tech celebrity also suggested that new government policies on immigration and investment in academia (not bailout) and incentivize venture capitalists and corporations to take more risks will boost innovation.

Estrin also suggested investors to measure a company’s CFC (capacity for change) – in addition to its EPS (earnings per share) – and place a value on this ability to invest in innovation.


Follow

Get every new post delivered to your Inbox.

Join 32 other followers